Kristien Esser

The global healthcare CDMO market is expected to grow from USD 250.19 billion in 2023 to USD 630.87 billion by 2033, with a CAGR of 9.69%. North America leads the market, holding a 41.56% share in 2023. Continuous innovations in drug discovery and manufacturing processes are driving the growth of the CDMO market. CDMOs adopt cutting-edge technologies, allowing biopharmaceutical companies to focus on drug discovery while CDMOs handle process development and manufacturing. North America, particularly the U.S., dominates due to significant outsourcing and a complex healthcare system. Meanwhile, Asia Pacific is emerging as a critical player, with India and China providing cost-effective solutions and focusing on novel therapeutic mechanisms. How can emerging regions like Asia Pacific leverage their growing CDMO capabilities to compete with established markets in North America and Europe? #Healthcare #CDMO #Pharma #Biotech #Innovation #Growth #NorthAmerica #AsiaPacific #DrugDevelopment #Manufacturing #Technology #Pharmaceuticals

13

🫁 DELFI Diagnostics, a developer of accessible blood-based #AI tests to enhance #cancer detection have announced the publication of ground-breaking #data from the companies L101 study. The report details the performance and potential of DELFI's FirstLook Lung test. This milestone study, led by top researchers in the field, marks a significant advancement in aiding #blood-based cancer detection. #satigo #cancer #AI #medtech #biotech #earlydetection #lungcancer #data

3

PM Group are #hiring a Senior #Process #Engineer in #Basel #Switzerland - Apply today: https://lnkd.in/eCGHzxEQ The role is to support the management and execution of #pharma projects throughout the full project life cycle from initiation to closeout. #Ingenieurin #Ingenieur #Anlagenbau #Prozessingenieur #lifescience

36

1 Comment

PM Group are #hiring a Senior #Process #Engineer in #Basel #Switzerland - Apply today: https://lnkd.in/eCGHzxEQ The role is to support the management and execution of #pharma projects throughout the full project life cycle from initiation to closeout. #Ingenieurin #Ingenieur #Anlagenbau #Prozessingenieur #lifescience

48

1 Comment

"According to the report, the Europe Precision Medicine market is predicted to be valued at approximately USD 17,132 million in 2018 and is expected to reach a value of around USD 40,487 million by 2025, at a CAGR of around 13.1% between 2019 and 2025." #Bioinformatics #Development #PrecisionMedicine #Research #Europe #MarketGrowth https://lnkd.in/efvMDqtV

9

📊 Quanticate x PhaseV Collab? 📈 *News from April 30th* The winds of change have swept through Quanticate, (Biometrics CRO) and Phase V (Clinical Trials Design Platform), as they embark on a transformative journey in the clinical trial landscape. In a strategic move unveiled Thursday, the partnership announced plans for a comprehensive cost-saving initiative totaling a significant investment. "As part of our ongoing evolution, we're implementing a strategic shift towards adaptive clinical trial services that will enhance our agility, drive operational efficiency, and prioritize investments in areas with the greatest potential to accelerate groundbreaking therapies to patients," remarked a spokesperson, echoing sentiments akin to other biotech players focusing on a strategic stance. The roadmap for this transformation extends through the coming year, with hints of changes already underway. Sources close to the partnership reveal recent adjustments to roles, suggesting the transition is well underway. Earlier discussions by Quanticate and Phase V hinted at a forthcoming transition period, emphasizing cost discipline and pipeline optimization, all with an eye on robust growth in the years ahead. In their latest update, the partnership underscores a laser focus on R&D programs poised to deliver substantial returns, suggesting potential realignments within their pipeline. Moreover, their M&A strategy is pivoting towards smaller, strategic acquisitions over larger-scale buyouts. As Quanticate and Phase V chart their course forward, one thing remains clear: while milestones are reached, the journey continues. The commitment to innovation remains unwavering, with a collective recognition that significant work lies ahead to ensure their adaptive clinical trial services benefit those in need." We often overlook the on-going innovations that occur within the life sciences but as we enter a new period with emergences of new technology and systems think about what areas within clinical trials are due for an upgrade? Check out the full article here - https://lnkd.in/g-BxNe22 What processes or systems can be streamlined in your line of work? Comment below! We are a community, we are CPL! #Biotech #Pharma #LifeScience #Biometrics #ClinicalSystems #ClinicalProcesses #CRO #Biometrics #ClinicalDevelopment

1

The radiopharmaceutical market is set to soar! It is projected to grow from $9B in 2023 to $26.5B by 2031! With rising cancer and Alzheimer’s cases, advancements in diagnostics, and demand for targeted treatments, healthcare is evolving fast. North America leads, but Asia-Pacific is catching up. Are we ready to meet the global demand for these cutting-edge therapies?

13

Ukraine has significant potential for conducting clinical trials due to its advanced infrastructure, skilled personnel, large patient pool, cost-effectiveness, and a favorable regulatory environment that is continuously updated to maintain competitiveness in the international market. * Before the full-scale war, Ukraine's clinical trials industry saw annual growth of 30%, with 2,500 public medical institutions conducting international clinical trials and around 500 trials taking place each year. * In 2023, the clinical trials sector began to recover. As of mid-2023, 344 clinical trials were extended, and 36 were launched. * Ukraine's regulatory framework for clinical trials is aligned with European legislation by 80-85%, with ongoing efforts to further harmonize the standards. In March 2024, the Ministry of Health updated Order No. 690, which outlines the procedures for conducting clinical trials of medicinal products and the review of clinical trial materials.    Explore our guide to learn more about opportunities in healthcare sector: https://guide.aequo.ua #rebuildukraine #guidetorebuildingukraine #investment #healthcare

11

The global Next Generation Cancer Diagnostics (NGCD) market is poised for significant expansion 🚀 The market is set to soar from $16.6B in 2023 to $64.6B by 2030, growing at a staggering CAGR of 21.4%. Innovations like liquid biopsy, ctDNA, CTC, and miRNA testing are revolutionizing diagnostics 💰 Genomic and proteomic advancements drive personalized medicine, improving patient outcomes and minimizing side effects. NGCD technologies in hospitals, labs, and research institutes are making care more precise and effective. #OncologyResearch #CancerDiagnostics #LiquidBiopsy #PersonalisedMedicine #LifeScienceNews #ElixirAssociates

5

🚨 MedTech Europe 2024 Facts & Figures Report is Out! 🚨 For those of you working in the medical technology industry, staying informed on key trends and industry data is essential. MedTech Europe has just issued their annual 2024 report packed with valuable insights that quantify the footprint of the industry across Europe. This report dives deep into the significant role medical technology plays in building sustainable healthcare systems, fostering economic growth, and enhancing Europe’s global competitiveness. It's an excellent resource for industry professionals looking to stay ahead. 🔗 Check it out here: https://lnkd.in/eS6feAzC #MedTech #Europe #IndustryNews #Healthcare #MedicalTechnology

3

1 Comment

💊 Are you a leader in pharma development and considering outsourcing? Outsourcing can offer major advantages in pharma, but success starts with asking the right questions. Our latest blog outlines 5 essential considerations to guide your strategy and highlights how Synergy Scientific Solutions provides the flexibility, expertise and dedicated management support needed for optimal results. From improving agility to strengthening supply chain transparency, discover how Synergy can make outsourcing work for your unique goals. Read the full blog here 👇 https://bit.ly/3AsbKH3 #Pharma #Outsourcing #Science #SupplyChain #Pharmaceuticals

6

The global radiopharmaceutical market is projected to soar to $26.51 billion by 2031, driven by advances in diagnostic imaging and targeted cancer therapies. These innovative treatments are transforming patient care by combining precision medicine with cutting-edge science. This growth highlights the increasing demand for next-gen solutions in oncology and beyond—an exciting space for biotech and pharmaceutical innovators. 🚀 As we see more investments and partnerships in this sector, it’s clear that radiopharmaceuticals are shaping the future of personalized healthcare. What do you think is next for this rapidly evolving field? Let’s discuss! 👇 #Biotech #Radiopharmaceuticals #Oncology #PrecisionMedicine #PharmaInnovation

13

Great insights here on the state of medtech VC funding, especially as we head into the second half of 2024! The 3% YoY growth and $3.3B deal value for Q2 2024 shows continued confidence in the space, with cardiovascular and diagnostics leading the way. 🚀 It's encouraging to see big deals like INSIGHTEC and BillionToOne making headlines, along with the Tempus AI IPO—a clear signal of optimism for the sector, even for companies still working toward profitability. While the drop in early-stage deals is a bit concerning, it’s good to remember that success at the later stages can eventually create more opportunities across the board. For those working on early-stage innovations: Keep pushing forward. The funding landscape is evolving, and with perseverance, opportunities will emerge. 💡 #Medtech #Innovation #Startup #VentureCapital #2024

3

Electronic Clinical Outcome Assessment (eCOA) Solution Market worth $4.1 billion by 2029 Download PDF Brochure: https://lnkd.in/dUZESfeM The size of global electronic clinical outcome assessment solution market in terms of revenue was estimated to be worth $1.9 billion in 2024 and is poised to reach $4.1 billion by 2029, growing at a CAGR of 16.3% from 2024 to 2029. 𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐏𝐫𝐨𝐟𝐢𝐥𝐞𝐬 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 IQVIA (US), MediData AG (US), @ICON Plc (Ireland), Signant Health (US), Clario (US), Oracle (US), Medable Inc. (US), Merative (US), Parexel International (MA) Corporation (US), Climedo Health GmbH (Germany), & Others 𝐎𝐭𝐡𝐞𝐫 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐭𝐡𝐚𝐭 𝐚𝐫𝐞 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐠𝐥𝐨𝐛𝐚𝐥𝐥𝐲 ArisGlobal CRF HEALTH GROUP LIMITED Covance CRIO eClinicalWorks Datatrak ERESEARCH TECHNOLOGY, INC Greenphire Medrio Bioclinica OmniComm Systems  PAREXEL Informatics, Inc. PHT Corporation Realtime Software Corporation Rave Technologies Inc. Symphony Clinical Researchar Arithmos Kayentis Trial By Fire Solutions Viedoc Veristat Almac Group Anju Software Ennov Medidata Solutions OmniComm Systems Saama Technologies,  DSG, Inc. Medrio Symphony Clinical Researchar  ClinDatrix, Inc. PRA Health Sciences #ecoa #clinicaltrials #patientreportedoutcomes #clinicalresearch #digitalhealth

1

⚕ Diagnostic Contract Manufacturing Market Set for Rapid Growth ⚕ The global Diagnostic Contract Manufacturing Market is expected to expand significantly, projected to grow from $25.7 billion in 2023 to $57.9 billion by 2031, with a CAGR of 10.78%. 💊 Market Expansion: This growth is driven by the increasing efficiency of outsourcing and advancements in technology across the diagnostic manufacturing sector. 💊 Innovative Applications: The market encompasses a range of devices and services, focusing on areas from infectious diseases to oncology within the In Vitro Diagnostic (IVD) space. 💊 Regional Insights: The Asia Pacific region is predicted to dominate market growth due to robust local industry presence and increasing chronic health issues. #DiagnosticManufacturing #HealthcareInnovation #MarketGrowth #UpendoStaffing #LoveWhatYouDo

3

📢 Exciting News from the MHRA! 📢 The Medicines and Healthcare products Regulatory Agency (MHRA) is proposing a new policy to streamline the approval process for medical devices in the UK. Here’s what you need to know: Key Points: 🔄 Automatic Market Access: Devices already approved by certain international regulators can enter the UK market without additional approval processes. 🌍 International Regulators: This will initially apply to devices approved by authorities in Australia, Canada, the EU, and the US. Implications: ⏱ Speedier Access: Expect faster availability of new, potentially life-saving technologies for UK patients. 📉 Reduced Bureaucracy: Recognising approvals from established international bodies will decrease the administrative burden on manufacturers and the MHRA. 🚀 Increased Market Appeal: The UK market becomes more attractive for medical device manufacturers, leading to a greater influx of innovative technologies. 🤝 Regulatory Harmonisation: This suggests a step towards greater alignment and mutual recognition of medical device regulations between the UK and major markets, fostering international cooperation. Considerations: 🔍 Quality and Safety Assurance: Safeguards will be in place to ensure devices meet high standards for safety and efficacy. 🛠 Implementation and Transition: Details on implementation and transitional arrangements will be crucial for manufacturers and healthcare providers to understand. This proposed policy could significantly impact the medical device landscape in the UK, promoting faster access to innovative treatments and potentially improving healthcare outcomes. We’ll be closely monitoring how this policy rolls out and its effects on the quality and safety of medical devices in the UK. #MedicalDevices #HealthcareInnovation #UKHealthcare #RegulatoryUpdates #MHRA #GlobalHealth 🌟

224

6 Comments

Move over #PPM #Healthcare #Services… #Pharma services is taking the lead for #PE investment dollars. Congrats to PitchBook on the launch of this new report! “Over the past two years, pharma services has emerged as the hottest area of healthcare for PE investment. The sector covers contract and outsourced services for the biopharmaceutical industry. Our Launch Report: Pharma Services kicks off with breakdowns of the sector's four segments: outsourcing, clinical services, consulting services, and manufacturing & distribution. Three key trends have powered growth and investment in pharma services: scientific advancements, a growing emphasis on specialty drugs, and consolidation opportunities for outsourcing organizations.” ONWARD

3